Description

This issue of Vital Signs, released on September 8, 2008, provides an strategic overview of the expansion of personalized medicine outside of oncologic PET. Additionally, a company spotlight is provided for Cell>Point, a company focused on the development of novel radiopharmaceutical agents for diagnostic and therapeutic applications in neurology, cardiology and oncology. Reimbursement and regulatory news from the FDA is also provided for the week of August 26, 2008.